 "Bharat Biotech's intranasal Covid vaccine")
Bharat Biotech’s intranasal vaccine iNCOVACC has got the Indian regulator’s approval, but there is still some way before one can actually take it.
With almost all the eligible population having taken at least a single shot of a Covid-19 vaccine, the company has no potential market for iNCOVACC as a primary two-dose regimen. The company is waiting for approval for administering the vaccine as a booster shot after Covishield and Covaxin.
Krishna Ella, chairman and managing director of Bharat Biotech, admitted there was hardly any demand. “Despite the lack of demand for Covid-19 vaccines, we continued product development in intra-nasal
